Redefining Glaucoma
Focused on the future
LIQID Medical is a medical technology company pioneering a new class of highly effective glaucoma devices
Founder
Dr. Daemon McClunan is an award-winning eye specialist who has pioneered the elimination of glaucoma through oculosubarachnoid shunting since 2015.
Dr McClunan founded LIQID Medical to facilitate the commercial development of devices which leverage this potentially game changing concept.
About us
Driven by the need to overcome the challenges of existing glaucoma therapies, LIQID Medical is pioneering the ground-breaking concept of oculosubarachnoid shunting.
Through oculosubarachnoid shunting, our devices are designed to self-regulate, optimise glaucoma control, and avoid the complications associated with bleb formation. Our aim is to create the most clinically effective, cost-saving, and quality of life improving solutions for severe and refractory glaucoma.
Our work has led to multiple scientific awards and the development of clinically proven patented ophthalmic devices. The OptiShunt and iPortVR have the potential to redefine treatment paradigms in glaucoma.
LIQID Medical recently initiated the GOSSIP study, a first-in-man clinical trial evaluating oculosubarachnoid shunting for the treatment of glaucoma. 6-month results indicate that oculosubarachnoid shunting is safe and highly effective in reducing mean intraocular pressure and the number of medications used by patients.
70% reduction in mean IOP
41mmHg → 12mmHg
LIQID Medical is privately held and based in Cape Town, South Africa. Cape Town is emerging as a major technology hub and the South African medical device industry conforms to the highest international standards since the implementation of strict SAHPRA regulations.
Our experienced and capable team remains focused on revolutionising the treatment of glaucoma for the benefit of patients, physicians and healthcare systems around the world.